Synairgen (LON:SNG) Stock Price Crosses Below 50 Day Moving Average of $19.03
Synairgen (LON:SNG) Stock Price Crosses Below 50 Day Moving Average of $19.03
Synairgen plc (LON:SNG – Get Rating) shares crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 19.03 ($0.23) and traded as low as GBX 17.28 ($0.20). Synairgen shares last traded at GBX 18.50 ($0.22), with a volume of 324,019 shares.
在週一的交易中，Synairgen plc(倫敦股票代碼：SNG-GET Rating)的股價跌破了50日移動均線。該股的50日移動均線為19.03英鎊(0.23美元)，交易價格低至17.28英鎊(0.20美元)。Synairgen的股票最後交易價格為18.50英鎊(0.22美元)，成交量為324,019股。
Synairgen Trading Up 0.7 %
Synairgen交易上漲0.7%
The firm has a fifty day moving average of GBX 19.03 and a two-hundred day moving average of GBX 24.08. The company has a current ratio of 6.35, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09. The company has a market cap of £37.24 million and a PE ratio of -0.76.
該公司的50日移動均線為19.03英鎊，200日移動均線為24.08英鎊。該公司的流動比率為6.35，速動比率為6.35，債務權益比率為0.09。該公司市值3724萬GB，市盈率為-0.76。
About Synairgen
關於Synairgen
(Get Rating)
(獲取評級)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有：治療新冠肺炎的乙型吸入型幹擾素SG001；治療感冒和流感引起的哮喘的乙型幹擾素吸入劑；治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨牀試驗；以及治療特發性肺纖維化的LXL2抑制劑。
Recommended Stories
推薦故事
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here's What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
- 贏得網絡博彩業的三大法寶
- 聖誕老人拉力賽？以下是需要發生的事情
- 鮑勃·艾格的迴歸會讓魔術迴歸迪士尼的股票嗎？
- Ardelyx是在2022年初下滑後的買入嗎
- 特斯拉目前處於兩年低點，現在是不是很划算？
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。